Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asset Turnover is linked to ROE % through Du Pont Formula. Jeevan Scientific Technology's annualizedROE % for the quarter that ended in Mar. 2026 was 8.94%. It is also linked to ROA % through Du Pont Formula. Jeevan Scientific Technology's annualizedROA % for the quarter that ended in Mar. 2026 was 6.03%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Jeevan Scientific Technology's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Jeevan Scientific Technology Asset Turnover Related Terms
Jeevan Scientific Technology Asset Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538837 vs VRTX, REGN, ALNY: Asset Turnover Comparison
For the Biotechnology subindustry, Jeevan Scientific Technology's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeevan Scientific Technology Asset Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jeevan Scientific Technology's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Jeevan Scientific Technology's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Jeevan Scientific Technology (BOM:538837) has a Asset Turnover of 0.20 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Jeevan Scientific Technology and its competitors.
Is Jeevan Scientific Technology's Asset Turnover too high?
Jeevan Scientific Technology's current Asset Turnover is 0.20. Overall, Jeevan Scientific Technology has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jeevan Scientific Technology's Asset Turnover compare to VRTX and REGN?
Jeevan Scientific Technology's Asset Turnover of 0.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Jeevan Scientific Technology and its competitors. Jeevan Scientific Technology's current Asset Turnover is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeevan Scientific Technology stock overvalued right now?
Based on GuruFocus' analysis, Jeevan Scientific Technology (BOM:538837) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹61.75, compared to a current price of ₹72.77 — trading 17.8% above its estimated fair value. The current Asset Turnover is 0.20. Jeevan Scientific Technology's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Jeevan Scientific Technology (BOM:538837), the current Asset Turnover is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeevan Scientific Technology (BOM:538837) Overvalued in 2026?
Based on GuruFocus' analysis, Jeevan Scientific Technology stock appears to be overvalued.
The current stock price of ₹72.77 is trading 17.8% above its estimated GF Value™ of ₹61.75.
GuruFocus considers Jeevan Scientific Technology to be Modestly Overvalued.
Key valuation signals for BOM:538837:
Asset Turnover: 0.20
GF Value™: ₹61.75 vs. price of ₹72.77 (17.8% above fair value)
No single metric tells the full story. See the BOM:538837 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeevan Scientific Technology Ltd is an India-based company engaged in providing clinical research and data management services. Jeevan Scientific is an independent clinical contract research organization, offering reliable, cost-effective, and technology-driven clinical research solutions to various clients across the globe. Its services offer high-value testing services, including bioanalytical services for small and large molecules, ranging across generics, biosimilars, and other new drugs. It operates in a single segment, namely clinical research services.
65GF Score
Get the complete analysis for BOM:538837
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538837 has been successfully added to your 
